Novartis’ Cosentyx wins NICE backing for non-radiographic axial spondyloarthritis
Axial spondyloarthritis affects approximately one in 200 people in the UK
Read More
Tag: axial spondyloarthritis
NICE backs Lilly’s Taltz for axial spondyloarthritis
Drug has been cleared for use in patients whose condition is not controlled well enough with conventional therapy
Read More
UCB’s Cimzia bags EU label extension
Drug is first biologic in Europe to be approved with a dose reduction label for axSpA patients
Read More
Lilly bags expanded EU approval for Taltz
Taltz has been granted an additional indication for the treatment of patients across the full axSpA spectrum
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
